FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
MOXEZA
moxifloxacin hydrochloride
Peak
OPHTHALMIC · SOLUTION/DROPS
2010
NDA8/100
MYDAYIS
dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate
Peak
Takeda
ORAL · CAPSULE, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 yearsolder
2017
NDA8/100
MYOVIEW
tetrofosmin
Peak
INJECTION · INJECTABLE
1996
NDA8/100
MYOVIEW 30ML
tetrofosmin
Peak
INJECTION · INJECTABLE
1996
NDA8/100
MYRBETRIQ
mirabegron
Peak
ORAL · TABLET, EXTENDED RELEASE
2012
NDA8/100
NAMENDA XR
memantine hydrochloride
Peak
AbbVie
ORAL · CAPSULE, EXTENDED RELEASE
2010
NDA8/100
NAMZARIC
memantine hydrochloride and donepezil hydrochloride
Peak
AbbVie
ORAL · CAPSULE, EXTENDED RELEASE
moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily
2014
NDA8/100
NESINA
alogliptin
Peak
Takeda
ORAL · TABLET
type 2 diabetes mellitustype 1 diabetes mellitus
2013
SMNDA8/100
NEXPLANON
etonogestrel
Peak
Merck & Co.
IMPLANTATION · IMPLANT
pregnancy in women of reproductive potential for up to 5 years
2006
NDA8/100
NEXTERONE
amiodarone hydrochloride
Peak
Baxter
INJECTION · INJECTABLE
2008
NDA8/100
NICORETTE
nicotine polacrilex
Peak
GSK
ORAL · TROCHE/LOZENGE
2009
NDA8/100
NINLARO
ixazomib
Peak
Takeda
ORAL · CAPSULE
combination with lenalidomidedexamethasone for the treatment of patients with multiple myeloma
2015
NDA8/100
NITROLINGUAL
nitroglycerin
Peak
SUBLINGUAL · AEROSOL
1985
NDA8/100
NITROLINGUAL PUMPSPRAY
nitroglycerin
Peak
SUBLINGUAL · SPRAY, METERED
1985
NDA8/100
NOCDURNA
desmopressin acetate
Peak
Ferring Pharmaceuticals
SUBLINGUAL · TABLET
2018
NDA8/100
NOCTIVA
desmopressin acetate
Peak
NASAL · SPRAY, METERED
2017
NDA8/100
NUCYNTA ER
tapentadol hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
2011
NDA8/100
NULIBRY
fosdenopterin hydrobromide
Peak
Sentynl Therapeutics
INTRAVENOUS · POWDER
mortality in patients with molybdenum cofactor deficiency (MoCD) Type A
2021
NDA8/100
OFEV
nintedanib
Peak
Boehringer Ingelheim
ORAL · CAPSULE
2014
SMNDA8/100
OLEPTRO
trazodone hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
2010
NDA8/100
OLYSIO
simeprevir sodium
Peak
Johnson & Johnson
ORAL · CAPSULE
2013
NDA8/100
ONEXTON
clindamycin phosphate and benzoyl peroxide
Peak
Bausch + Lomb
TOPICAL · GEL
2008
NDA8/100
ONUREG
azacitidine
Peak
Bristol Myers Squibb
ORAL · TABLET
2020
NDA8/100
OPANA ER
oxymorphone hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
2006
NDA8/100